Mar 27, 2014 - The efficacy of minoxidil was also confirmed by the findings of the mean changes .... affected by androgen during their prepubertal phase.
Oral Presentations March 27, 2014 Lotus Suites 3-4
March 27, 2014 English Presentations
Minoxidil 2% lotion for eyebrow enhancement : A randomized, double-blind, placebo-controlled, spilt-face comparative study Saridpong Lee MD, Chuchai Tanglertsampan MD MBA, Mingkwan Tanchotikul MD, Nigun Worapunpong MD. ABSTRACT : LEE S, TANGLERTSAMPAN C, TANCHOTIKUL M, WORAPUNPONG N. MINOXIDIL 2% LOTION FOR EYEBROW ENHANCEMENT : A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SPILT-FACE COMPARATIVE STUDY. DEPARTMENT OF DERMATOLOGY, SCHOOL OF ANTI-AGING AND REGENERATIVE MEDICINE, MAE FAH LUANG UNIVERSITY HOSPITAL, BANGKOK, THAILAND. Background : Topical minoxidil is US Food and Drug Administration-approved for the treatment of androgenetic alopecia in men and women. It can also be applied to enhance eyebrows. However, there is no study comparing minoxidil lotion with placebo for eyebrow enhancement. Objectives : The purpose of this study is to compare the efficacy and safety of minoxidil 2% lotion versus placebo for eyebrow enhancement. Materials and Methods : Forty patients were randomly assigned to treatment of minoxidil 2% lotion on one eyebrow and placebo on the contralateral side. Patients were instructed to apply one drop of assigned solutions twice a day for 16 weeks. Follow-up visits were scheduled every 4 weeks for efficacy and safety evaluation. The primary end-point for efficacy assessment was the global photographic score. The secondary end-points were the changes in eyebrow diameter and number, subject satisfaction and safety evaluation. Results : Among the 40 enrolled subjects, 39 (97.5%) patients completed the study. The majority of subjects were female (26/39, 66.7%). The average age was 30.64 ± 5.72 years. Based on the global photographic scores, there was a statistically significant difference between minoxidil and placebo beginning at week 8 and throughout the rest of the study. The efficacy of minoxidil was also confirmed by the findings of the mean changes from baseline in eyebrow diameter and count. In addition, the subjects were significantly more satisfied with the minoxidil treatment than placebo. All side-effects were mild to moderate and resolved spontaneously within a few days after the onset of symptoms. Conclusion : The minoxidil group achieved significantly better results in all measured outcomes compared to the placebo group. Side-effects were minor and did not preclude patients from continuing the study. Our study suggested that minoxidil 2% is a safe and effective treatment for eyebrow hypotrichosis. (J Dermatol, accepted)
Key word : minoxidil, lotion, topical, eyebrow, placebo
28
March 27, 2014 English Presentations @ABCDEFG : HIJDKLMNOP QRFSTU, VWVCE XCYNZTKOHC[MC\]P, [K^N_`Ca XC\bVXKกdT, \KกC\XP `eMC\]dPMNOP. 2% f[\GกRKDKTbTVC^\HghSeC@กheกeiXdj\กheZkeKaZXK@bX_GN_\BKY` : กheOlกJhZAUE@กC@EhSTGก Q@@HdF[ QTimกmnDACYN 2 Djh\ ! "# $% &'ก ) * $ +, -./ '#0.-123&14$56 7 8+97# : .;< "# .'#0;=1> KกDWL[=OJQ`cgก]9EJUWA:aA^9Ye>Pก9JoGBW9JOL:nCA=Kก@A=\=ABD>DoY9U:GH DYZH>JKก]9OJQ`< DEJG8LD:G8LกKLก9JoGBW9JWDNG8J>8BRDoY9U:GH `K]UกheOlกJh : ก9J_Ah8K =i9JV>P `nIE{_8 12 Q=:GกDEF=กCMV8OJQhUmnกWKก OB8กCMV 1 QJKPb OB8[\IEJA8OJQ 6.05 NJ.@Pก9J_AhK8 TCUกCMV8BR;BIJKLก9JJKก]9BI_8ก9JoGB;NJT>UD@ON;=BR 10 =CUQJKbP hi9=_= 4 QJKbPNABNV>กK= JI>8CUe>P`=:i9ก9JJKก]9;8CUe>P`ก:GHBGTCU;BI`C D:G8LD:V9กKLก9JJKก]9BI_8ก9J JKก]9TLL8BRDoY9U:GH) Wi9SJKLOJQ`
_V9DกABh9ก ก9Je>PN=D>PLJAD_qNV>ก[= ก9JJKก]9 `nIE{_88KPDEF=EJUDBf=:GH:I9:98[=EzhhMLK= DQ8PNV>ก9JJKก]9BI_8 DCD@>JRD>>JRDLG8< \=ABTLVPWV_= OB8YLก[SP`8V9PW= `CXodmeiHNBP : DYZH>cgก]9EJUWA:aA^9Ye>PDCD@>JRD>>JRDLG8PeI>NV>กJUBnกWK=SCKPTCUeI>WV_=J89PQRe>P JV9Pก98 [=EzhhMLK=8KP;= OB8DoY9U>8V9P8AHP [=`nIE{_8OJQeI>WUDกfBDPA= :GH; TNVYLQ_9cgก]9ก9JDECGH8=TECP:9PJKPWG_A:89e>PกJUBnกTCUeI>TCUQ_99ก9J`ZH=WUDกfBDPA= >9ก9JeI>>KกDWL TCUJUBKLW9J>KกDWL[=DCZ>B กKLก9JDECGH8=TECP:9PJKPWG_A:89 `K]UกheOlกJh : cgก]9Q_9P^9YmV98JKPWGe>P`nEI {_8WUDกfBDPA=:GH; 79 Q=:GHmV98^9Y JKPWGe>P D:I9 กJUBnกWK=SCKP TCUWUOYก YLQ_9>KกDWLWUDกfBDPA=:GH;KกDWL[=JU8UD_C9 2 Ep 43 Q= (63.23%) @gHPEJUก>LBI_8 eI>>KกDWL (synovitis) 19 Q= (23.75%) DWI=D>f=>KกDWL (Enthesitis) 6 Q= (7.5%) =Ab_>KกDWL (Dactylitis) 11 Q= (13.75 %) TCUE_BSCKP 31 Q= (37.5%) ^9YmV98JKPWGYLQ_98V9P;JกfN99ก9JeI>>KกDWL (p=0.63) QV9>GD>W>9JR (ESR; erythrocyte sedimentation rate) (mean ESR 17.5 vs. 26, p=0.280) QV9@G>9JRYG (CRP; C-reactive protein) (mean CRP 2.66 vs. 4.82, p=0.492) QV9>A=DN>JRCnQA= 6 (IL-6) (mean IL-6 3.58 vs. 3.96, p=0.767) Hedm : `nIE{_8eI>>KกDWLWUDกfBDPA=:GH;9ก9JeI>>KกDWLTCUก9JDECGH8=TECPe>PกJUBnกTCUeI> :9PJKPWG_A:89;BI TNV;9ก9JeI>>KกDWLD>f=>KกDWL:GH>9hDกABegb=^98SCKP TNV;B, ^9YmV98:9PJKPWG_A:89, eI>>KกDWL, DWI=D>f=>KกDWL, =Ab_>KกDWL
49
March 27, 2014 English Presentations
The prevalence of vitamin D deficiency in Thai psoriasis patients with metabolic syndrome and liver fibrosis Saneerat Porntharukchareon MD, Nattapon Ngarmjiratam MD, Ploychompoo Srisuwanwattana MD, Jamrus Pongpit MD, Natta Rajatanavin MD. ABSTRACT : PORNTHARUKCHAREON S,** NGARMJIRATAM N,** SRISUWANWATTANA P,** PONGPIT J,* RAJATANAVIN N.** THE PREVALENCE OF VITAMIN D DEFICIENCY IN THAI PSORIASIS PATIENTS WITH METABOLIC SYNDROME AND LIVER FIBROSIS. *DIVISION OF GASTROENTEROGY, **DIVISION OF DERMATOLOGY, FACULTY OF MEDICINE RAMATHIBODI HOSPITAL, MAHIDOL UNIVERSITY, BANGKOK, THAILAND. Background : Vitamin D plays an important role in bone health and recently its role in non-skeletal system including immune regulation was demonstrated. Vitamin D deficiency has been reported in psoriasis patient especially those with metabolic syndrome. Studies have also found an association between vitamin D deficiency and non-alcoholic fatty liver disease in normal population that lead to liver fibrosis. However, the relationship between vitamin D deficiency in psoriasis patients with liver fibrosis has not been established. Objective : To define prevalence of vitamin D deficiency and metabolic syndrome in Thai psoriatic patients and study the association of serum 25-hydroxyvitamin D level with metabolic syndrome and liver fibrosis Methods : A cross-sectional study was conducted at dermatology clinic of Ramathibodi hospital between August 2013 and October 2013 .One hundred and thirty eight patients with chronic plaque psoriasis without phototherapy treatment and vitamin D supplement were invited to participate in this study. Demographic data, comorbidities, disease severity, treatment modalities and exposure time to sunlight were collected. Serum 25-hydroxyvitamin D, PTH, calcium, phosphate blood sugar, lipid profile, and related blood chemistry were measured. Transient elastography (fibroscan) to evaluate liver fibrosis was performed in 116 patients Results : The mean serum 25(OH)D level of 138 psoriasis patients was 26.24±7.41ng/ml. The prevalence of vitamin D deficiency [25(OH)D levels < 20ng/ml] and vitamin D insufficiency [25(OH)D levels < 30ng/ml] was 23.9% and 69.6 % ,respectively. The prevalence of metabolic syndrome was 49.3%. The mean serum 25(OH)D levels of patients with and without metabolic syndrome were not significant different, 27.08±7.71 ng/ml and 25.43±7.08 ng/ml ,respectively.(p =0.191) There were no significant differences in the prevalence of vitamin D deficiency and insufficiency between psoriasis patient with or without metabolic syndrome. 22.1% vs 25.7%, (p=0.615) and 66.2% vs 72.9%,(p=0.394),respectively. Fibroscan showed significant liver fibrosis (fibroscan > 7.1Kpa) in 9.5% of psoriasis patients. Serum vitamin D level was not significant different between patients with or without liver fibrosis, 24.74±9.07 ng/ml and 26.61±7.46 ng/ml (p= 0.440), respectively. Conclusions : Prevalence of vitamin D deficiency in Thai psoriasis patients was 23.9%. No significant association between low serum 25-hydroxyvitamin D level and metabolic syndrome or significant liver fibrosis in Thai psoriasis patients.
Key word : vitamin D deficiency, psoriasis, metabolic syndrome, liver fibrosis 50
March 27, 2014 English Presentations @ABCDEFG : OhtUeCX\P Me]heCกJPZkeKa,* tCzMT Nh[kKe]ee[,* MTGEV[MW OeUHd`eet`C}\h,* kgheCH MNJPMKO,** tC•zh eCVXi\h`K\.* กheOlกJhB`h[Vdก_GNsh`i`KXh[K\DUX^ghv\pWjmw`EbeBHiZกuDZNK\QTiB`h[HC[MC\]P_GNeiDC@`KXh[K\DUX^ghกC@ กTdF[beBZ[Xi@GTKกQTish`iMCNp€DAU^XC@v\pWjmw`EbeBHiZกuDZNK\v\fAE *
